- Home
- DSGN vs BIOA Comparison
DSGN vs BIOA Comparison
Compare DSGN & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- BIOA
- Stock Information
- Founded
- DSGN 2017
- BIOA 2015
- Country
- DSGN United States
- BIOA United States
- Employees
- DSGN N/A
- BIOA N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- DSGN Health Care
- BIOA Health Care
- Exchange
- DSGN Nasdaq
- BIOA Nasdaq
- Market Cap
- DSGN 208.9M
- BIOA 175.7M
- IPO Year
- DSGN 2021
- BIOA 2024
- Fundamental
- Price
- DSGN $6.54
- BIOA $5.56
- Analyst Decision
- DSGN
- BIOA Hold
- Analyst Count
- DSGN 0
- BIOA 4
- Target Price
- DSGN N/A
- BIOA $5.67
- AVG Volume (30 Days)
- DSGN 173.8K
- BIOA 184.5K
- Earning Date
- DSGN 11-06-2025
- BIOA 11-06-2025
- Dividend Yield
- DSGN N/A
- BIOA N/A
- EPS Growth
- DSGN N/A
- BIOA N/A
- EPS
- DSGN N/A
- BIOA N/A
- Revenue
- DSGN N/A
- BIOA $3,863,000.00
- Revenue This Year
- DSGN N/A
- BIOA N/A
- Revenue Next Year
- DSGN N/A
- BIOA N/A
- P/E Ratio
- DSGN N/A
- BIOA N/A
- Revenue Growth
- DSGN N/A
- BIOA N/A
- 52 Week Low
- DSGN $2.60
- BIOA $2.88
- 52 Week High
- DSGN $7.77
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- DSGN 54.51
- BIOA 60.29
- Support Level
- DSGN $5.88
- BIOA $5.55
- Resistance Level
- DSGN $7.59
- BIOA $6.00
- Average True Range (ATR)
- DSGN 0.51
- BIOA 0.28
- MACD
- DSGN -0.06
- BIOA 0.03
- Stochastic Oscillator
- DSGN 37.42
- BIOA 61.69
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.